Oncology outcomes
Higher tumour EZH2 tracks portal-vein invasion in HCC
Open access · cc by · source: Europe PMC
In 66 resected HCC tumours, EZH2 mRNA was higher than in paired nontumour liver and high expression associated with portal-vein invasion (79% vs 39%), without a significant disease-free survival difference.
Study at a glance
- Design
- Cohort — Surgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR
- N
- N=66 · Median-split high vs low tumour expression (n=33 each)
- Population
- Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver
- Outcome
- EZH2 expression vs portal-vein invasion and disease-free survival
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Mean tumour EZH2 (0.34±0.52) exceeded nontumour levels (0.07±0.09, P<0.0001). Portal-vein invasion was more common in the high-expression group (26/33, 79%) than the low-expression group (13/33, 39%; P<0.001). Disease-free survival did not differ significantly between groups. Authors conclude EZH2 upregulation may mark malignant potential, especially vascular invasion.
Methodology
Authors quantified EZH2 mRNA by real-time RT-PCR in tumour and matched nontumour liver from 66 surgical HCC patients, split tumours at the median into high vs low expression (n=33 each), and correlated expression with clinicopathological features and disease-free survival.
Limitations
No significant DFS difference means EZH2 here is not a proven survival biomarker in this cohort. Association with portal-vein invasion is clinicopathological, not proof that lowering EZH2 prevents invasion. Sample is a single-centre surgical series.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Higher tumour EZH2 mRNA associates with portal-vein invasion after HCC resection.
In 66 surgical HCC tumours, EZH2 mRNA exceeded matched nontumour liver and high expression tracked portal-vein invasion (79% vs 39%) without a significant disease-free survival split — a clinicopathological progression signal, not a proven survival assay in this cohort.
Evidence for the claim as stated.
Validated DNA methylation signatures can separate HCC from surrounding liver.
Illumina promoter arrays in 30 paired HCC/surrounding samples produced a validated methylation signature that distinguished tumour from adjacent liver independent of major risk factors, with other panels linked to progression and survival after therapy.
Scope note — related HCC progression theme, but single-gene mRNA vs multi-CpG epigenetic classifier
Limits the claim's scope: a different population, assay, or outcome.
AMSC exosomes can deliver miR-122 and sensitise HCC models to chemotherapy.
miR-122–loaded adipose MSC exosomes raised miR-122 in HepG2 cells, downregulated resistance-linked targets (including CCNG1/ADAM10/IGF1R), and increased chemosensitivity in vitro and in xenograft combinations — a preclinical strategy, not a finished patient protocol.
Scope note — human surgical association study, not an exosome therapy experiment
Limits the claim's scope: a different population, assay, or outcome.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
Evidence for the claim as stated.
EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
- A 22-gene classifier flags early metastasis after prostatectomy
- HDAC2 IHC tracks shorter PSA relapse in prostate cancer
- Five integrated genomic subgroups track prostate-cancer relapse risk
- DNA methylation signatures separate HCC from nearby liver